Lympro Recent Developments In the company's most
Post# of 30028
Posted On: 08/05/2014 11:53:57 AM
Lympro Recent Developments
In the company's most recent update, all positive findings were verified. AMBS has been focusing on creating a pathway to reimbursement for the product launch for LymPro. It appears they have recently done so, and are ready to move forward with marketing.
In addition, more clinical verification and analytic validation has been performed, another CLIA (Clinical Laboratory Improvement Amendments) requirement. CLIA exists for the protection of patient's from any potential misgivings, from the individual lab tech, all the way on up to test producers.
Amarantus plans to commercialize LymPro during the second half of 2014
In the company's most recent update, all positive findings were verified. AMBS has been focusing on creating a pathway to reimbursement for the product launch for LymPro. It appears they have recently done so, and are ready to move forward with marketing.
In addition, more clinical verification and analytic validation has been performed, another CLIA (Clinical Laboratory Improvement Amendments) requirement. CLIA exists for the protection of patient's from any potential misgivings, from the individual lab tech, all the way on up to test producers.
Amarantus plans to commercialize LymPro during the second half of 2014
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼